Martin Williams

Martin Williams, PhD, is Executive Director of Psychedelic Research in Science & Medicine (PRISM) and Vice-President of Entheogenesis Australis (EGA). Martin’s background is in medicinal chemistry and pharmacology, and more recently in psychedelic clinical research.

He has been a co-investigator on several Australian clinical trials of psychedelic-assisted psychotherapy, including the St Vincent’s Hospital Melbourne study of psilocybin-assisted psychotherapy in palliative care; the Monash PsiConnect neuroimaging study of psilocybin with mindfulness meditation; the Swinburne PsiloDep pilot study of psilocybin-assisted therapy for treatment-resistant depression; and the IMPACT-2 study of methylone with therapy for PTSD.

Martin has been an articulate advocate for psychedelic medical research and the evidence-based clinical translation of psychedelic-assisted therapies for almost twenty years. He has co-authored numerous academic papers providing an Australian perspective on psychedelic therapies, including an influential Perspectives paper in Frontiers in Psychiatry, and was lead co-editor of the special topic issue of Frontiers, Beyond Psilocybin: Exploring the Clinical Potential of Novel and Alternative Psychedelics. Martin remains committed to the careful, pragmatic translation of psychedelic medicine from research to clinical practice.

Connect: www.prism.org.au